Dengue virus infection - a review of pathogenesis, vaccines, diagnosis and therapy
- PMID: 36493993
- PMCID: PMC10194131
- DOI: 10.1016/j.virusres.2022.199018
Dengue virus infection - a review of pathogenesis, vaccines, diagnosis and therapy
Abstract
The transmission of dengue virus (DENV) from an infected Aedes mosquito to a human, causes illness ranging from mild dengue fever to fatal dengue shock syndrome. The similar conserved structure and sequence among distinct DENV serotypes or different flaviviruses has resulted in the occurrence of cross reaction followed by antibody-dependent enhancement (ADE). Thus far, the vaccine which can provide effective protection against infection by different DENV serotypes remains the biggest hurdle to overcome. Therefore, deep investigation is crucial for the potent and effective therapeutic drugs development. In addition, the cross-reactivity of flaviviruses that leads to false diagnosis in clinical settings could result to delay proper intervention management. Thus, the accurate diagnostic with high specificity and sensitivity is highly required to provide prompt diagnosis in respect to render early treatment for DENV infected individuals. In this review, the recent development of neutralizing antibodies, antiviral agents, and vaccine candidates in therapeutic platform for DENV infection will be discussed. Moreover, the discovery of antigenic cryptic epitopes, principle of molecular mimicry, and application of single-chain or single-domain antibodies towards DENV will also be presented.
Keywords: Cross reaction; DENV; Development; Diagnostic; Therapeutic.
Copyright © 2022. Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
![Fig 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10194131/bin/gr1.gif)
![Fig 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10194131/bin/gr2.gif)
![Fig 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10194131/bin/gr3.gif)
![Fig 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10194131/bin/gr4.gif)
Similar articles
-
Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine.Front Cell Infect Microbiol. 2020 Oct 22;10:572681. doi: 10.3389/fcimb.2020.572681. eCollection 2020. Front Cell Infect Microbiol. 2020. PMID: 33194810 Free PMC article. Review.
-
Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.EBioMedicine. 2020 Oct;60:102991. doi: 10.1016/j.ebiom.2020.102991. Epub 2020 Sep 16. EBioMedicine. 2020. PMID: 32949997 Free PMC article.
-
Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.J Virol. 2020 Aug 31;94(18):e00745-20. doi: 10.1128/JVI.00745-20. Print 2020 Aug 31. J Virol. 2020. PMID: 32611757 Free PMC article.
-
Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development.Front Immunol. 2019 Jun 11;10:1316. doi: 10.3389/fimmu.2019.01316. eCollection 2019. Front Immunol. 2019. PMID: 31244855 Free PMC article. Review.
-
Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.J Virol. 2017 Feb 14;91(5):e02041-16. doi: 10.1128/JVI.02041-16. Print 2017 Mar 1. J Virol. 2017. PMID: 28031369 Free PMC article.
Cited by
-
Square the Circle: Diversity of Viral Pathogens Causing Neuro-Infectious Diseases.Viruses. 2024 May 15;16(5):787. doi: 10.3390/v16050787. Viruses. 2024. PMID: 38793668 Free PMC article. Review.
-
Exploring the therapeutic potential of DV-B-120 as an inhibitor of dengue virus infection.J Virol. 2024 Apr 16;98(4):e0125823. doi: 10.1128/jvi.01258-23. Epub 2024 Mar 28. J Virol. 2024. PMID: 38546211
-
Using Computational Simulations Based on Fuzzy Cognitive Maps to Detect Dengue Complications.Diagnostics (Basel). 2024 Mar 2;14(5):533. doi: 10.3390/diagnostics14050533. Diagnostics (Basel). 2024. PMID: 38473004 Free PMC article.
-
Severe dengue in the intensive care unit.J Intensive Med. 2023 Sep 28;4(1):16-33. doi: 10.1016/j.jointm.2023.07.007. eCollection 2024 Jan. J Intensive Med. 2023. PMID: 38263966 Free PMC article. Review.
-
Review of dengue, zika and chikungunya infections in nervous system in endemic areas.Arq Neuropsiquiatr. 2023 Dec;81(12):1112-1124. doi: 10.1055/s-0043-1777104. Epub 2023 Dec 29. Arq Neuropsiquiatr. 2023. PMID: 38157877 Free PMC article. Review.
References
-
- Abrahamsson, N., Coulombier, D., Danielsson, N., Derrough, T., Domanovic, D., Jansà, J.M., Korhnan, T., Mollet, T., Sudre, B., Szegedi, E., et al. (2016). Rapid Risk Assessment. Zika virus disease epidemic: potential association with microcephaly and Guillain–Barré syndrome. Fourth update, 9 March 2016.
-
- Ahmed N.H., Broor S. Comparison of NS1 antigen detection ELISA, real time RT-PCR and virus isolation for rapid diagnosis of dengue infection in acute phase. J. Vector Borne Dis. 2014;51(3):194–199. - PubMed
-
- Akey D.L., Brown W.C., Dutta S., Konwerski J., Jose J., Jurkiw T.J., DelProposto J., Ogata C.M., Skiniotis G., Kuhn R.J., et al. Flavivirus NS1 structures reveal surfaces for associations with membranes and the immune system. Science. 2014;343(6173):881–885. doi: 10.1126/science.1247749. - DOI - PMC - PubMed
-
- Alcon S., Talarmin A., Debruyne M., Falconar A., Deubel V., Flamand M. Enzyme-linked immunosorbent assay specific to Dengue virus type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections. J. Clin. Microbiol. 2002;40(2):376–381. doi: 10.1128/jcm.40.02.376-381.2002. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical